Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
once-daily trientine tetrahydrochloride
- Development stage
- Unknown
- Lead developer
- Orphalan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The once-daily trientine tetrahydrochloride formulation (900mg TETA 4HCl Once Daily Formulation) is an investigational oral formulation of trientine tetrahydrochloride (TETA 4HCl) developed by Orphalan for the treatment of Wilson's disease. Trientine tetrahydrochloride is a copper chelator that binds to excess copper ions in the body, forming a stable complex that is excreted in the urine. This once-daily formulation consists of 300mg trientine base tablets, allowing patients to take a single daily dose of 900mg (3 x 300mg tablets) instead of the twice-daily regimen required by the currently marketed Cuprior® formulation (150mg tablets). This once-daily dosing is designed to reduce the treatment burden and improve patient adherence. The formulation is currently being evaluated in Phase III clinical trials (such as the TRADITiONAL study) for the first-line treatment of Wilson's disease.
- Other names
- 900mg TETA 4HCl Once Daily Formulationonce-daily TETA 4HCltrientine tetrahydrochloride once-daily formulation
Beyond the preview
Go deeper on once-daily trientine tetrahydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on once-daily trientine tetrahydrochloride.